Livanova PLC Aktie News

LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced completion of the CORE-VNS study further validating effectiveness of VNS Therapy for severe focal seizures in children & adults.

LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced CORE-VNS 24-month data show adjunctive VNS Therapy associated with substantial reduction in generalized tonic-clonic seizures.

LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC announced it initiated the process with U.S. CMS to seek reconsideration of national Medicare coverage for VNS Therapy in depression.

LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time. The discussion will be available to all interested parties...

LivaNova PLC (NASDAQ:LIVN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Briana Gotlin – Vice President, Investor Relations Vladimir Makatsaria – Chief Executive Officer Ahmet Tezel – Chief Innovation Officer Alex Shvartsburg – Chief Financial Officer Stephanie Bolton – President, Global Epilepsy Conference Call Participants Rick Wise – Stifel David Roman – Goldm...

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis ...

LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders ...

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2025 results on Wed., May 7, 2025, at 1 p.m. London time (8 a.m. Eastern Time).